Abselion is celebrating a significant achievement winning the coveted Bioprocessing Industry Association 2023 award for Next-Gen Analytics at the annual industry gathering. This recognition comes in light of Amperia, a groundbreaking benchtop tool designed to revolutionize at-line protein and viral particle analysis.
This award was decided by vote from the audience, which was comprised of industry members familiar with the persistent challenges of lengthy turnaround times and delays associated with centralized analytical labs. The appreciation and endorsement of Amperia, an at-line analytics solution for biologics, underscore the tool’s transformative potential within the industry.
Abselion has initiated pilot projects since the summer of 2023, with plans to launch the product for commercial use early 2024. The company’s vision extends beyond its initial success, aiming to broaden Amperia’s applications across various viral particles and establish a strong presence in academia, pharma, biotech, and CRO.
The Bioprocessing Industry Association award underscores Abselion’s commitment to innovation and its potential to revolutionize the field of analytical chemistry. This recognition from this prestigious industry association solidifies Abselion’s status as an innovator in the world of bioprocessing and analytical technology.
Read more: https://shorturl.at/bluC3